If LLL12, a novel pSTAT3 inhibitor, is applied to prevent STAT3 from phosphorylation, the stemness of prostate cancer cells is inihibited, resulting in significant reduction of cancer cell proliferation in primary cultures from patients with high Gleason grades. Here, STAT3 is linked to prostate carcinoma.